Personalized glucose-lowering effect of chiglitazar in type 2 diabetes.

ABSTRACT: Chiglitazar (carfloglitazar) is a peroxisome proliferator-activated receptor pan-agonist presenting non-inferior glucose-lowering efficacy with sitagliptin in patients with type 2 diabetes. To delineate the subgroup of patients with greater benefit from chiglitazar, we conducted a machine learning-based post-hoc analysis in two randomized controlled trials. We established a character phenomap based on 13 variables and estimated HbA_1c decline to the effects of chiglitazar in reference to sitagliptin. Out of 1,069 patients, 63.3% were found to have greater reduction in HbA_1c levels with chiglitazar, while 36.7% showed greater reduction with sitagliptin. This distinction in treatment response was statistically significant between groups (p_interaction<0.001). T

SUBMITTER: Huang Q 

PROVIDER: S-EPMC10628820 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature